Roseman B J, Buzdar A U, Singletary S E
Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
J Surg Oncol. 1997 Nov;66(3):215-20. doi: 10.1002/(sici)1096-9098(199711)66:3<215::aid-jso11>3.0.co;2-0.
Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast cancer. Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists. Advances in hormonal pharmacology have placed hormonal therapy alongside surgery and radiation therapy as a standard treatment option for women with advanced breast cancer. The purpose of this article is to update surgeons on the current use of hormonal agents for treatment of advanced breast cancer in postmenopausal women, and to review the aromatase inhibitors, a new line of hormonal agents for the treatment of advanced breast cancer.
自1896年引入卵巢切除技术以来，外科医生一直参与转移性乳腺癌的治疗。然而，随着更新的激素和化疗方案的出现，药物治疗逐渐取代手术，成为转移性乳腺癌的首选治疗方法。因此，转移性乳腺癌的治疗在很大程度上已从外科医生转向肿瘤内科医生。激素药理学的进展使激素治疗与手术和放射治疗一起，成为晚期乳腺癌女性的标准治疗选择。本文旨在向外科医生介绍目前用于治疗绝经后女性晚期乳腺癌的激素药物的使用情况，并综述芳香化酶抑制剂，这是一种用于治疗晚期乳腺癌的新型激素药物。
